Biomea Fusion, Inc. (BMEA)

NASDAQ: BMEA · Real-Time Price · USD

1.485

+0.055 (3.85%)

May 16, 2025, 2:46 PM - Market open

Biomea Fusion Employees

Biomea Fusion had 106 employees as of December 31, 2024. The number of employees increased by 3 or 2.91% compared to the previous year.

Employees

106

Change (1Y)

3

Growth (1Y)

2.91%

Revenue / Employee

n/a

Profits / Employee

-$1,213,462

Market Cap

55.79M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	106	3	2.91%
Dec 31, 2023	103	20	24.10%
Dec 31, 2022	83	32	62.75%
Dec 31, 2021	51	39	325.00%
Dec 31, 2020	12	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

BMEA News

1 day ago - Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia - GlobeNewsWire
10 days ago - Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
6 weeks ago - Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
6 weeks ago - Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewsWire
7 weeks ago - Biomea Fusion Announces Leadership Transition - GlobeNewsWire
7 weeks ago - Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose - GlobeNewsWire
2 months ago - Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
2 months ago - Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes - GlobeNewsWire